Henry NL, et al. - Results of SWOG S1202 indicated that after treatment with duloxetine (a serotonin norepinephrine reuptake inhibitor) vs placebo pain was improved by 12 weeks in patients with aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS). This combined with the prior observation that pain responses to interventions differ between obese and nonobese patients, researchers examined the influence of obesity on response to duloxetine therapy. A total of 299 AI-treated postmenopausal women with stage I to III (AJCC 7th Edition) breast cancer who developed new or worsening average pain were enrolled, randomized to duloxetine or placebo, and treated for 12 weeks in SWOG S1202. In this trial, more analgesic benefit from duloxetine was evident among obese patients with AIMSS vs nonobese patients.